All Articles
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Read More ›
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer. Read More ›
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more.
Read More ›
It is well known that cancer treatment is often associated with serious adverse side effects, but conventional care is often focused on cure and survival, rather than on a holistic approach to patient care, suggests Nerissa Wood, BSN, RN, OCN, Director, Tulane Comprehensive Cancer Clinic, New Orleans, LA. Read More ›
This detailed article of codes related to bladder cancer is intended to assist practice managers and other healthcare providers and payers to ensure the proper use of coding and billing information associated with the treatment of patients with bladder cancer. Read More ›
To effectively address socioeconomic disparities in healthcare, particularly regarding cancer survivorship, it is critical that we improve our understanding of the material, psychosocial, and behavioral dimensions of financial well-being, said Reginald D. Tucker-Seeley, MA, ScM, ScD, Edward L. Schneider Chair in Gerontology, University of Southern California, Los Angeles, at the 2017 AACR Science of Cancer Health Disparities Conference. Read More ›